Atomoxetine (Strattera) 40 mg Twice Daily Does Not Require Tapering
Atomoxetine can be discontinued abruptly without tapering, as explicitly stated in the FDA label and supported by clinical trial evidence. 1
Direct FDA Guidance
The FDA-approved prescribing information for Strattera is unequivocal: "STRATTERA can be discontinued without being tapered." 1 This is the definitive guidance that should direct clinical practice.
Supporting Clinical Evidence
A prospective, placebo-controlled study specifically examined discontinuation effects after 9-10 weeks of continuous atomoxetine therapy in both children and adults with ADHD 2. Key findings include:
- No discontinuation syndrome developed when atomoxetine was stopped abruptly
- No statistically significant differences in discontinuation-emergent adverse events between patients stopping atomoxetine versus those on placebo
- ADHD symptoms worsened after discontinuation but did not rebound below pretreatment levels
- Tapering is not necessary when discontinuing atomoxetine 2
Critical Distinction from Alpha-2 Agonists
This guidance contrasts sharply with other ADHD medications. Guanfacine and clonidine (alpha-2 agonists) must be tapered due to risk of rebound hypertension upon abrupt discontinuation 3, 4. Atomoxetine, as a norepinephrine reuptake inhibitor, does not carry this cardiovascular risk.
Practical Implementation
For your patient on 40 mg twice daily (80 mg total daily):
- Stop both doses immediately on the chosen discontinuation date
- Monitor for return of ADHD symptoms over subsequent weeks
- No dose reduction schedule is required
- Capsules should not be opened; if final doses are given, they should be taken whole 1
Important Caveats
While tapering is unnecessary for atomoxetine itself, consider:
- Symptom monitoring: ADHD symptoms will gradually return but should not worsen beyond baseline 2
- Suicidality monitoring: The black box warning for suicidal ideation applies during treatment and dose changes, though discontinuation studies showed no increased risk 4
- Alternative treatment planning: If discontinuing due to inadequate response rather than remission, have the next treatment strategy ready
This straightforward approach is unique to atomoxetine among ADHD medications and represents a significant practical advantage in clinical management.